The Evolving Future of PCSK9 Inhibitors

Rosenson, Robert S., Hegele, Robert A., Fazio, Sergio, Cannon, Christopher P.·2018·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2018.04.054

Cited by (273)

Items 201–273 of 273

  1. Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren
    Yara Azar, Marie‐Hélène Gannagé‐Yared, Elie Naous, Carine Ayoub, Yara Abou Khalil, Elise Chahine, Sandy Elbitar, Youmna Ghaleb, Cathérine Boileau, Mathilde Varret et al. · 2022 · Metabolites
  2. Research Progress in the Clinical Treatment of Familial Hypercholesterolemia
    Jing-Yan Ai, Peng-Cheng Zhao, Wen Zhang, Guo-Wu Rao · 2023 · Current Medicinal Chemistry
  3. INNOVATIVE WAYS OF IMPROVING MEDICINE, PSYCHOLOGY AND BIOLOGY
    Denis Vladlenov, Halyna I. Khrebtii, Галина Коваль, О.С. Вакаров, Олена Іванівна Карбованець, Людмила Голомб, Валентина Іванівна Петросова, Ілона Руснак, Вероника Кулачек, Ярослав Кулачек et al. · 2023 · Іnternational Science Group eBooks
  4. Discovery of [5,5′‐bibenzo[d][1,3]dioxol]‐6‐substituted amine derivatives as potent proprotein convertase subtilisin/kexin type 9 inhibitors
    Dongqi Zhu, Hongyu Qin, Xiaojing Wang, Yuping Jia, Xuejian Wang, Lei Zhang · 2023 · Chemical Biology & Drug Design
  5. Traitement médical de l’artériopathie chronique oblitérante des membres inférieurs (AOMI) : la folie des grandeurs ?
    J.-P. Laroche · 2019 · JMV-Journal de Médecine Vasculaire
  6. New Chapter in the PCSK9 Book: Oral Inhibition of PCSK9 Binding to the LDL Receptor With a Macrocyclic Peptide
    Ulf Landmesser, Umidakhon Makhmudova · 2023 · Circulation
  7. Proprotein convertase subtilisin/kexin type 9 inhibitors: prospects for cholesterol-lowering therapy in type 2 diabetes
    Victoria A Serhiyenko, Alexandr A. Serhiyenko · 2023 · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
  8. PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines
    A. A. Nekipelova, Renad Nikolaevich Alyautdin · 2023 · Safety and Risk of Pharmacotherapy
  9. Review on PCSK9: A Pertinent Therapeutic Target in Cardiovascular Disease
    Sonia Kaur Singh, Manas Kumar Jha · 2023 · Current Bioactive Compounds
  10. Role of Bailout Gene-Silencing Therapy in Plaque Lipid Reduction: Intravascular Imaging Study
    Kārlis Trušinskis, Baiba Kokina, Maris Lapsovs, Mairita Karantajere, Evija Kanašniece, Laima Caunīte, Sanda Jēgere, Inga Narbute, Dace Sondore, Aļona Grāve et al. · 2025 · Cardiology
  11. The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis
    Rubela Ray, Arhum Mahmood, Raheel Chaudhry, Mohd Diya Masmoum, Muhammad Talha, Fahad I. Siddiqui, Imdad Ullah · 2025 · Current Cardiology Reviews
  12. Current Advancements in the Diagnosis and Management of Mild-to-moderate Coronary Stenosis
    Cuimei Guo, Haizhu Gao, Xinxin Bian, Nan Lin, Lijun Gan, Xueying Chen · 2025 · Reviews in Cardiovascular Medicine
  13. Unraveling the temporal sequence of coronary atherosclerosis modification with lipid-lowering therapies through intravascular imaging: a narrative review
    Mingzhuang Sun, Zhenze Yu · 2026 · Frontiers in Cardiovascular Medicine
  14. Base editing milestone for familial hypercholesterolemia
    Robert S. Rosenson, Sascha N. Goonewardena · 2026 · Nature Medicine
  15. Piperazine-Derived Diamine Lipid Nanoparticles Targeting to the Liver for Delivering Clustered Regularly Interspaced Short Palindromic Repeat Editing of PCSK9 to Durably Maintain Plasmatic Low-Density Lipoprotein Cholesterol in Low Levels
    Shifeng Zhao, Shiyun Huang, Nan Li, Neng Wang, Zhitao Yu, Xiaoyu Liang, Zhenhuang Yang, Hongchang Guo · 2026 · ACS Applied Bio Materials
  16. Potential beneficial effect of treatment with PCSK9 inhibitors on vascular endothelial dysfunction: a systematic review and meta-analysis
    Christina Antza, Panagiota Anyfanti, Charalampia Savva, Konstantinos Malandris, Andrej Belančić, Yusuf Ziya Şener, Evangelia Chaida, Dimitrios Poulis, Vasilios Kotsis · 2026 · Expert Review of Clinical Pharmacology
  17. Prediction of the Statin responders with radiomics
    Sang‐Eun Lee, Youngtaek Hong, Juyeong Jung, Ji Min Sung, Daniele Andreini, Mouaz Husayn Al-Mallah, Matthew Jay Budoff, Filippo Cademartiri, Kavitha M. Chinnaiyan, Jung Hyun Choi et al. · 2026 · Journal of cardiovascular computed tomography
  18. Tratamiento de la hipertrigliceridemia leve-moderada
    Pablo Pérez‐Martínez, Francisco Pérez‐Jiménez · 2021 · Clínica e Investigación en Arteriosclerosis
  19. Reduction of Cardiovascular Risk Using Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Acute Coronary Syndrome: A Systematic Review
    Ahmad M Rabih, Ahmad Niaj, Aishwarya Raman, Manish Uprety, Maria Jose Calero, Maria Resah B Villanueva, Narges Joshaghani, Nicole Villa, Omar Badla, Raman Goit et al. · 2023 · Cureus
  20. Assessing opinion on lower LDL-cholesterol lowering, and the role of newer lipid-reducing treatment options
    Derek Leslie Connolly, Azfar Zaman, Nigel E. Capps, Steve C Bain, Kevin Fernando · 2023 · British Journal of Cardiology
  21. Combined Use of Statin and PCSK9 Inhibitor in a Pregnant Woman with Possible Familial Hypercholesterolemia and Coronary Artery Stenosis
    Yusaku Shimizu, Tae Yokouchi-Konishi, Chizuko Aoki-Kamiya, Mai Temukai, Kotaro Hizuka, Masami Sawada, A. Kakigano, N. Iwanaga, Takeshi Kanagawa, Kota Murai et al. · 2025 · Journal of atherosclerosis and thrombosis
  22. PCSK9 gene Polymorphism and Assessment of Cardiovascular Risk and Prognosis in Patients With Hyperlipidemia: A Retrospective Cohort Study
    Aibibanmu Aizezi, Fanhua Meng, Xiaolei Li, Yanpeng Li, Jialin Abuzhalihan, Fen Liu, Min-Tao Gai, Dilare Adi, Yi-Tong Ma · 2025 · Journal of Clinical Hypertension
  23. Association of Copper with Atherosclerosis and Treatment Strategies
    Jiawei Li, Yi Lin, Lingna Zhang, Lufan Shen, Yuyuan Lu, Hong Wang, Xiaojie Chen, Yushun Kou, Yiyuan Wang, Rui Ma et al. · 2025 · Journal of Cardiovascular Translational Research
  24. ApoE-Knockout Mice: What are New Achievements of this Model of Atherosclerosis?
    Barbara Lorkowska-Zawicka, Jacek Jawień · 2021 · Acta Scientific Pharmaceutical Sciences
  25. May need more comprehensive approach to residual risks in well controlled hypertensive patients
    Toru Suzuki, Daisuke Kamimura, Hiromichi Wakui, Kouichi Tamura · 2020 · Hypertension Research
  26. Atherosclerosis: Cholesterol Management
    Scott D. Edmondson, Duane A. Burnett, Harry R. Davis · 2021 · Wiley eBooks
  27. Reinforcing Adherence to Lipid-lowering Therapy after an Acute Coronary Syndrome: A Pragmatic Randomized Controlled Trial
    Stefanos Zafeiropoulos, Ioannis T. Farmakis, Αναστάσιος Κάρτας, Alexandra Arvanitaki, Konstantinos Arvanitakis, Vasileios Nevras, Areti Pagiantza, Stavros P. Zanos, George A. Giannakoulas · 2020 · Research Square
  28. Sequential Proofreading Enhances Specificity and Potency of CRISPR-CasX-based Epigenetic Repressors
    Emeric J. Charles, Ross White, Ryan Tran, Amanda Mok, Lea Alice Kiefer, Kirsten A. Reimer, Ashley T Wong, Sterling Ripley-Phipps, Natalie Goh, T.C. Stevenson Keller et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  29. Novel Therapies for Dyslipidemia
    Olta Tafaj-Reddy · 2019 · IntechOpen eBooks
  30. Hiperkolesterolemia Familiarra: patofisiologia, diagnostikoa eta tratamendua
    U. Galicia, Jone Amuategi, Shifa Jebari‐Benslaiman, A. Larrea, Kepa B. Uribe, Helena Ostolaza, Cesar Martin, Asier Vicente Benito · 2020 · Osagaiz osasun-zientzien aldizkaria
  31. Guideline recommendations, clinical trial data, and new and emerging therapies
    John Lindsley · 2021 · The American Journal of Managed Care
  32. Long-Term Glycemic Control for Stroke Survivors
    Dong-Wan Kang · 2021 · Stroke revisited
  33. Dyslipidemias
    Cezary Wójcik · 2022 · Springer eBooks
  34. Tratamiento actual más allá de las estatinas en la hipercolesterolemia: cuanto más bajo mejor en la prevención de las enfermedades ateroscleróticas
    Enrique Gómez-Álvarez, Alejandro Alcocer Chauvet, Kevin R. Hernández‐Flores · 2021 · Cardiovascular and Metabolic Science
  35. Reinforcing Adherence to Lipid-lowering Therapy after an Acute Coronary Syndrome: A Pragmatic Randomized Controlled Trial
    Stefanos Zafeiropoulos, Ioannis T. Farmakis, George A. Giannakoulas, Αναστάσιος Κάρτας · 2020 · Research Square
  36. Dyslipidemias
    Cezary Wójcik · 2020 · Springer eBooks
  37. Inhibidores de PCSK9 en enfermedad cardiovascular
    Paul Mondragón‐Terán, Amy R. Rojas-Noverón · 2022 · Revista mexicana de enfermedades inflamatorias inmunomediadas
  38. Medikamentöse Therapie der Fettstoffwechselstörungen im Kindesalter
    Karl Otfried Schwab, Jürgen Doerfer · 2022 · Springer eBooks
  39. Acute impact of the early application of alirocumab on lipoprotein (a) and interleukin-6 in patients with unstable angina pectoris: a retrospective before-after study
    Zhen Yu Xu, Lu Lu Zhang, Sheng Huang Wang, Yong Wang · 2022 · Research Square
  40. Advanced therapeutics for targeting atherosclerosis
    Shome Sankar Bhunia, Utsab Debnath · 2023 · Elsevier eBooks
  41. Proteomic analysis of 92 circulating proteins and their effects in cardiometabolic diseases
    Corinne Carland, Grace Png, Anders Mälarstig, Pik Fang Kho, Stefan Gustafsson, Karl Michaëlsson, Lars Lind, Emmanouil Tsafantakis, Maria Karaleftheri, George V. Dedoussis et al. · 2023 · Research Square
  42. Special Patient Populations
    Gregory G. Schwartz · 2023 · Elsevier eBooks
  43. Statins in Patients With Established Heart Failure: Time for Reflection
    Bertram Pitt, Robert S. Rosenson · 2023 · Journal of Cardiovascular Pharmacology
  44. RETRACTED ARTICLE: circABCA3 knockdown relieves hypoxia-induced human cardiac microvascular endothelial cell dysfunction by targeting the miR-671-5p/PCSK9 axis
    Hui Hui, Gaowa Zhao, Mingliang Du, Qin Yu · 2023 · Cell Stress and Chaperones · Retracted
  45. Nuevos fármacos hipolipemiantes
    Fernando Isidro Lago Deibe, Raquel del Río Rodríguez, Mabel Castro García, Carolina Suárez Blanco, Pablo Moldes Peña · 2023 · FMC - Formación Médica Continuada en Atención Primaria
  46. PCSK9 inhibitors ameliorate arterial stiffness in ACS patients: evidences from mendelian randomization, cohort studies and basic experiments
    Linghao Xu, Liang Wang, Yuanqi Wang, Yiqiong Wang, Yuanzhen Jiang, Peizhao Du, Jing Cheng, Chunsheng Zhang, Ruijie Wang, Tiantian Jiao et al. · 2024 · Research Square
  47. Causal Relationship between Pcsk9 Inhibitor and Atrial Fibrillation: A Drug Target Mendelian Randomization Study
    Qiang Wang, Zihong Yang, Peizhuang Zhao, Xin Lin, Shuping Wen, Xinlong Zhang, Yaobing Xu · 2025 · SSRN Electronic Journal
  48. Low-density lipoprotein cholesterol levels and treatment intensity in secondary prevention of patients with ischaemic heart disease in the primary care setting: a real-world data registry study
    Núria Sánchez-Ruano, Anna Fibla-Matamoros, Carlos Falces, Encarna Sánchez, Antoni Sisó‐Almirall, Luis González‐de Paz · 2025 · BJGP Open
  49. Additional file 1 of Comprehensive mendelian randomization analysis of plasma proteomics to identify new therapeutic targets for the treatment of coronary heart disease and myocardial infarction
    Sun, Ziyi, Yun, Zhangjun, Lin, Jianguo, Sun, Xiaoning, Qingqing Wang, Duan, Jinlong, Li, Cheng, Xiaoxiao Zhang, Xu, Siyu, Zeqi Wang et al. · 2024 · Figshare
  50. Additional file 3 of PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis
    Chen, Ding-Qiang, Xu, Wen-Bin, Xiao, Ke-Yi, Zhiqiang Que, Feng Jinyi, 孙乃坤, Cai, Di-Xin, Gang Rui · 2024 · Figshare
  51. Additional file 7 of PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis
    Chen, Ding-Qiang, Xu, Wen-Bin, Xiao, Ke-Yi, Que, Zhi-Qiang, Feng Jinyi, 孙乃坤, Cai, Di-Xin, Gang Rui · 2024 · Figshare
  52. Additional file 2 of Comprehensive mendelian randomization analysis of plasma proteomics to identify new therapeutic targets for the treatment of coronary heart disease and myocardial infarction
    Sun, Ziyi, Yun, Zhangjun, Lin, Jianguo, Sun, Xiaoning, Qingqing Wang, Duan, Jinlong, Li, Cheng, Zhang, Xiaoxiao, Xu, Siyu, Zeqi Wang et al. · 2024 · Figshare
  53. Additional file 1 of Proteomic analysis of 92 circulating proteins and their effects in cardiometabolic diseases
    Corinne Carland, Grace Png, Anders Mälarstig, Pik Fang Kho, Stefan Gustafsson, Michaelsson, Karl, Lind, Lars, Emmanouil Tsafantakis, Maria Karaleftheri, George V. Dedoussis et al. · 2024 · Figshare
  54. Additional file 6 of PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis
    Chen, Ding-Qiang, Xu, Wen-Bin, Xiao, Ke-Yi, Que, Zhi-Qiang, Feng Jinyi, Sun, Nai-Kun, Cai, Di-Xin, Gang Rui · 2024 · Figshare
  55. Additional file 2 of Proteomic analysis of 92 circulating proteins and their effects in cardiometabolic diseases
    Corinne Carland, Grace Png, Anders Mälarstig, Pik Fang Kho, Stefan Gustafsson, Michaelsson, Karl, Lind, Lars, Emmanouil Tsafantakis, Maria Karaleftheri, George V. Dedoussis et al. · 2024 · Figshare
  56. Additional file 1 of PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis
    Chen, Ding-Qiang, Xu, Wen-Bin, Xiao, Ke-Yi, Zhiqiang Que, Feng Jinyi, Sun, Nai-Kun, Cai, Di-Xin, Gang Rui · 2024 · Figshare
  57. Additional file 5 of PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis
    Chen, Ding-Qiang, Xu, Wen-Bin, Xiao, Ke-Yi, Que, Zhi-Qiang, Feng Jinyi, Sun, Nai-Kun, Cai, Di-Xin, Gang Rui · 2024 · Figshare
  58. Additional file 2 of Effect of alirocumab on cataracts in patients with acute coronary syndromes
    Gaspard Suc, Gregory G. Schwartz, Shaun G. Goodman, J. Wouter Jukema, Garen Z. Manvelian, Yann Poulouin, Robert C. Pordy, Michel Scemama, Michael J. Szarek, Philippe Gabríel Steg · 2023 · Figshare
  59. Additional file 1 of Effect of alirocumab on cataracts in patients with acute coronary syndromes
    Gaspard Suc, Gregory G. Schwartz, Shaun G. Goodman, J. Wouter Jukema, Garen Z. Manvelian, Yann Poulouin, Robert C. Pordy, Michel Scemama, Michael J. Szarek, Philippe Gabríel Steg · 2023 · Figshare
  60. Additional file 4 of PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis
    Chen, Ding-Qiang, Xu, Wen-Bin, Xiao, Ke-Yi, Zhiqiang Que, Feng Jinyi, Sun, Nai-Kun, Cai, Di-Xin, Gang Rui · 2024 · Figshare
  61. Additional file 2 of PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis
    Chen, Ding-Qiang, Xu, Wen-Bin, Xiao, Ke-Yi, Zhiqiang Que, Feng Jinyi, Sun, Nai-Kun, Cai, Di-Xin, Gang Rui · 2024 · Figshare
  62. Le rôle du récepteur aux LDL et de PCSK9 dans le diabète de type 2
    Stéphane Ramin‐Mangata · 2020 · theses.fr (ABES)
  63. Rôle de la phosphatase alcaline non spécifique du tissu "TNAP" dans la calcification des plaques d’athérosclérose
    Lynn Kawtharany · 2022 · theses.fr (ABES)
  64. Clinical identification of familial chylomicronemia syndrome and novel therapeutic options
    Shyann Hang, Robert Alexander Hegele · 2026 · Expert Review of Cardiovascular Therapy
  65. Nanoparticle-Based PCSK9 Inhibition in Viral Infections: Evaluating Clinical Limitations and Advancing Therapeutic Strategies
    Moeen Fuad Dababneh, Bahjat Alhasso, Abdulkareem Shareef, Ashishkumar Kyada, H Malathi, Laxmidhar Maharana, Dinesh Puri, Harshit Gupta, N.A. Yarmukhamedova, Hayder Naji Sameer et al. · 2026 · Journal of Pharmaceutical Innovation
  66. Atherosclerosis features in rheumatic diseases – focus on peripheral artery disease
    Alexandr Ceasovschih, Alina Dima, Javier Rodríguez‐Carrio, Anastasia Balta, Raluca-Elena Alexa, Bianca Codrina Morărașu, Cătălina Lionte, Fotios Barkas, Maciej Banach, Victorița Șorodoc et al. · 2026 · Frontiers in Immunology
  67. Knowledge, Attitudes, and Practices Regarding PCSK9 Inhibitors Among Healthcare Professionals: Exploring Behavioral Pathways and the Intermediary Role of Attitude
    Chao Zhao, Nuan Wang, Dayong Shen, Laiyun Zhu, Guofang Chen · 2026 · Journal of Multidisciplinary Healthcare
  68. Association between PCSK9 targeted therapy and the risk of stroke and dementia: A meta-analysis of randomized controlled trials
    Vikash Jaiswal, Novonil Deb, Fakhar Latif, abhigan babu Shrestha, Vamsi Garimella, Nishat Shama, Sahas Reddy Jitta, Sidra Naz, Tushar Kumar, Shazia Khan et al. · 2026 · The American Journal of Medicine
  69. LRRC57/RABIN is a presynaptic inhibitor of Rab GTPases in glutamatergic neurons
    Dušan Garić, Jonathan G. Murphy, Brett J.W. Teubner, Christopher M. Davenport, Chablis D. Shreffler, Laura J. Janke, Woo Jung Cho, Zhiping Wu, Meghan G. McReynolds, Sarayut Phasuk et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  70. Enlicitide, a Novel Oral Macrocyclic Peptide PCSK9 Inhibitor for Lipid Lowering: A Systematic Review and Meta-Analysis
    Burcu Yağmur, Elif İjlal Çekirdekçi · 2026 · Journal of Cardiovascular Development and Disease
  71. Impact of Evolocumab on LDL‐Cholesterol and Cardiovascular Outcomes in Patients With Established CVD: Systematic Review and Meta‐Analysis
    Anika Goel, Muhammad ABDULLAH, Hemeesh Tandel, Affaf Mahmood, Muhammad Mukhlis, K. Sai Varun Reddy, Arun Kumar Maloth, Anchit Chauhan, Ameer Awashra, Amogh Verma et al. · 2026 · Endocrinology Diabetes & Metabolism
  72. BindingDB Entry 50020256: Small molecule inhibitors of PCSK9. SAR investigations of head and amine groups.
    BindingDB · 2024 · UC San Diego
  73. BindingDB Entry 50018519: Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment.
    BindingDB · 2024 · UC San Diego